Gaurav Maini, an analyst from LifeSci Capital, has initiated a new Buy rating on Liquidia Technologies (LQDA).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gaurav Maini has given his Buy rating due to a combination of factors that highlight Liquidia’s strong commercial momentum and improving fundamentals. He points to the rapid uptake of Yutrepia in both pulmonary arterial hypertension and PH-ILD, noting that prescription growth has been robust despite the product only launching in mid-2025, and that revenue has already scaled to a meaningful level.
Maini also emphasizes that Liquidia has reached profitability for a second consecutive quarter, supported by Yutrepia’s performance and a solid cash position that can fund continued investment in new programs. He views the balanced adoption across PAH and PH-ILD, the growing willingness of physicians to switch patients from existing prostacyclin therapies, and the planned exploratory studies as evidence of substantial remaining market opportunity and a durable growth trajectory.
In another report released today, Needham also maintained a Buy rating on the stock with a $54.00 price target.